López LJC, López NJC, Ruiz RR, González RM

Language: Spanish
References: 27
Page: 29-40
PDF size: 431.74 Kb.

ABSTRACT

Medication-related osteonecrosis of the jaws is possibly one of the most neglected and overlooked pathologies today in both dental and medical specialties. This article aims to give a current approach to its incidence, pathophysiology, diagnosis, staging and possible management, as well as to present a case of long evolution which underwent various treatments in its different stages of the disease.

REFERENCES

1. Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial surgeons' position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg. 2022; 80 (5): 920-943.

2. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg. 2014; 72 (10): 1938-1956.

3. Marx RE. Oral and intravenous bisphosphonate–induced osteonecrosis of the jaws: history, etiology, prevention, and treatment. 2nd edition. 2nd ed. Chicago, IL.: Quintessence; 2019. p. 379.

4. Khan AA, Rios LP, Sándor GK, Khan N, Peters E, Rahman MO et al. Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol. 2011; 38 (7): 1396-1402.

5. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res. 2015; 30 (1): 3-23.

6. Lombard T, Neirinckx V, Rogister B, Gilon Y, Wislet S. Medication-related osteonecrosis of the jaw: new insights into molecular mechanisms and cellular therapeutic approaches. Stem Cells Int. 2016; 2016: 8768162.

7. Wat WZM. Current controversies on the pathogenesis of medication-related osteonecrosis of the jaw. Dent J (Basel). 2016; 4 (4): 38.

8. Khominsky A, Lim M. "Spontaneous" medication-related osteonecrosis of the jaw; two case reports and a systematic review. Aust Dent J. 2018; 63 (4): 441-454.

9. Ruggiero SL. Diagnosis and staging of medication-related osteonecrosis of the jaw. Oral Maxillofac Surg Clin North Am. 2015; 27 (4): 479-487.

10. Moraschini V, de Almeida DCF, Figueredo CM, Calasans-Maia MD. Association between biomarkers and medication-related osteonecrosis of the jaws: a systematic review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 127 (6): 504-515.

11. Wadia R. Biomarkers and MRONJ. Br Dent J. 2019; 226 (10): 794.

12. Simon J, Michael JR. Bone cancer primary bone cancers and bone metastases. Chapter 51. 2nd ed. Academic Press; 2014. p. 736.

13. Patntirapong S, Poolgesorn M. Alteration of macrophage viability, differentiation, and function by bisphosphonates. Oral Dis. 2018; 24 (7): 1294-1302.

14. Zhu W, Xu R, Du J, Fu Y, Li S, Zhang P et al. Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw. FASEB J. 2019; 33 (4): 5208-5219.

15. Aghaloo T, Hazboun R, Tetradis S. Pathophysiology of osteonecrosis of the jaws. Oral Maxillofac Surg Clin North Am. 2015; 27 (4): 489-496.

16. Treister NS, Sook-Bin W. Chapter 107: Bisphosphonate-associated osteonecrosis of the jaws. In: Rosen CJ, Compston JE, Lian JB, eds. Primer on the metabolic bone diseases and disorders of mineral metabolism. 7th ed. Hoboken, NJ, USA: John Wiley & Sons, Inc.; 2009. pp. 505-509.

17. He L, Sun X, Liu Z, Qiu Y, Niu Y. Pathogenesis and multidisciplinary management of medication-related osteonecrosis of the jaw. Int J Oral Sci. 2020; 12 (1): 30.

18. Bradford WW, O'Ryan F. Management of medication-related osteonecrosis of the jaw. Oral Maxillofacial Surg Clin N Am. 2015; 27 (4): 517-525.

19. Nicolatou-Galitis O, Schiodt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 127 (2): 117-135.

20. Wu H, Moser C, Wang HZ, Hoiby N, Song ZJ. Strategies for combating bacterial biofilm infections. Int J Oral Sci. 2015; 7 (1): 1-7.

21. Delanian S, Chatel C, Porcher R, Depondt J, Lefaix JL. Complete restoration of refractory mandibular osteoradionecrosis by prolonged treatment with a pentoxifylline-tocopherol-clodronate combination (PENTOCLO): a phase II trial. Int J Radiat Oncol Biol Phys. 2011; 80 (3): 832-839.

22. Freiberger JJ, Padilla-Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW et al. What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. J Oral Maxillofac Surg. 2012; 70 (7): 1573-1583.

23. Bedogni A, Saia G, Bettini G, Tronchet A, Totola A, Bedogni G et al. Long-term outcomes of surgical resection of the jaws in cancer patients with bisphosphonate-related osteonecrosis. Oral Oncol. 2011; 47 (5): 420-424.

24. Heufelder MJ, Hendricks J, Remmerbach T, Frerich B, Hemprich A, Wilde F. Principles of oral surgery for prevention of bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014; 117 (6): e429-e435.

25. Pautke C, Bauer F, Otto S, Tischer T, Steiner T, Weitz J et al. Fluorescence-guided bone resection in bisphosphonate-related osteonecrosis of the jaws: first clinical results of a prospective pilot study. J Oral Maxillofac Surg. 2011; 69 (1): 84-91.

26. Curi MM, Cossolin GS, Koga DH, Zardetto C, Christianini S, Feher O et al. Bisphosphonate-related osteonecrosis of the jaws--an initial case series report of treatment combining partial bone resection and autologous platelet-rich plasma. J Oral Maxillofac Surg. 2011; 69 (9): 2465-2472.

27. Vescovi P, Manfredi M, Merigo E, Guidotti R, Meleti M, Pedrazzi G et al. Early surgical laser-assisted management of bisphosphonate-related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 101 treated sites with long-term follow-up. Photomed Laser Surg. 2012; 30 (1): 5-13.